MedPath

Treatment of chronic subdural hematoma by corticosteroids : a prospective randomized study

Phase 1
Conditions
chronic subdural hematoma
MedDRA version: 18.0 Level: LLT Classification code 10049163 Term: Chronic subdural hematoma System Organ Class: 100000004863
Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Registration Number
EUCTR2015-000927-96-FR
Lead Sponsor
CHU of Rennes
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Recruiting
Sex
Not specified
Target Recruitment
226
Inclusion Criteria

-Age = 18 years old
-With chronic or subacute, uni- or bilateral subdural hematoma
-Confirmed by cerebral CT scan without contrast enhancement
-Without clinical and radiological signs of severity
-Written informed consent from patients or thier next of kin
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range

Exclusion Criteria

-Contraindication for methylprednisolone
-Previous surgery for chronic subdural hematoma during the past 6 months
-Pre-existing severe dementia
-Existing neurological pathology that can be associated with dementia
-Patients treated with corticosteroids
-Adults legally protected (under judicial protection, guardianship or supervision), persons deprived of their liberty

Study & Design

Study Type
Interventional clinical trial of medicinal product
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Main Objective: show that a treatment with methylprednisolone can decrease the need for surgical treatment in patients with chronic subdural hematoma without clinical or radiological signs of severity;<br> Secondary Objective: assess the effect of methylprednisolone on :<br> -quality of life evolution<br> -morbidity and mortality<br> -radiological evolution of the lesions<br> ;Primary end point(s): rate of surgical treatment of the chronic subdural hematoma;Timepoint(s) of evaluation of this end point: at one month
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath